Keyphrases
T Cells
100%
CD19
100%
Chimeric Antigen Receptor T-cell Therapy
100%
Large B-cell Lymphoma
100%
Relapsed or Refractory
71%
Confidence Interval
42%
CD19 chimeric Antigen Receptor T Cells
28%
Durable Response
14%
Adult Patients
14%
Chimeric Antigen Receptor T Cells (CAR-T)
14%
Non-relapse Mortality
14%
Hazard Ratio
14%
High Incidence
14%
High Mortality
14%
Early Relapse
14%
Progression-free
14%
Mortality Hazard
14%
Progression-free Survival
14%
Marrow Transplantation
14%
Immune Effectors
14%
Univariable Analysis
14%
Poor Performance Status
14%
Research Registry
14%
Annualized Relapse Rate
14%
Cytokine Release Syndrome
14%
Histological Variants
14%
Primary Refractory
14%
Axicabtagene Ciloleucel
14%
Neurologic Syndrome
14%
Medicine and Dentistry
T Cell
100%
Large-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Progression Free Survival
28%
Chimeric Antigen Receptor T-Cell
14%
Hazard Ratio
14%
Cumulative Incidence
14%
Neurologic Disease
14%
Cytokine Release Syndrome
14%
Axicabtagene Ciloleucel
14%
Diseases
14%